SCM
TNGX icon

Superstring Capital Management’s Tango Therapeutics TNGX Stock Holding History

Superstring Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-474,955
Closed -$1.47M – 50
2024
Q4 		$1.47M Sell
474,955
-124,093
-21% -$576K 1.27% 22
2024
Q3 		$4.61M Buy
599,048
+483,477
+418% +$4.61M 4.04% 11
2024
Q2 		$992K Buy
+115,571
New +$893K 1.25% 23

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Superstring Capital Management's TNGX Position: Q1 2025 in Review

Superstring Capital Management sold out of Tango Therapeutics (TNGX) in Q1 2025, closing a stake of 474,955 shares — an estimated $1.47M sold.

Superstring Capital Management first reported a position in TNGX in Q2 2024 and held it in 3 quarters. The position peaked at $4.61M in Q3 2024. 122 funds tracked by Wall St. Rank hold TNGX as of Q1 2025.

  • Superstring Capital Management reported no remaining Tango Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Superstring Capital Management sold 474,955 Tango Therapeutics shares in Q1 2025, an estimated $1.47M.
  • Superstring Capital Management first reported a position in Tango Therapeutics in Q2 2024 and held it in 3 quarters.
  • Superstring Capital Management's Tango Therapeutics position peaked at $4.61M in Q3 2024.
  • 122 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2025.

Based on Superstring Capital Management's 13F filing for Q1 2025, filed 15 May 2025.